Axon Enterprise, Inc. (NASDAQ:AXON) Director Sells $380,990.00 in Stock

Axon Enterprise, Inc. (NASDAQ:AXON) Director Michael Garnreiter sold 1,000 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $380.99, for a total transaction of $380,990.00. Following the completion of the transaction, the director now owns 27,259 shares in the company, valued at approximately $10,385,406.41. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Axon Enterprise Price Performance

Axon Enterprise stock opened at $389.74 on Friday. The stock has a market capitalization of $29.45 billion, a P/E ratio of 113.96, a P/E/G ratio of 10.34 and a beta of 0.94. The company’s fifty day moving average price is $344.06 and its 200 day moving average price is $316.19. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.52 and a current ratio of 2.88. Axon Enterprise, Inc. has a 1 year low of $189.12 and a 1 year high of $391.55.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The business had revenue of $504.00 million for the quarter, compared to analyst estimates of $478.35 million. During the same quarter last year, the business earned $0.80 earnings per share. The company’s revenue for the quarter was up 34.5% compared to the same quarter last year. As a group, equities research analysts anticipate that Axon Enterprise, Inc. will post 1.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on AXON shares. Craig Hallum increased their price objective on shares of Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Jefferies Financial Group began coverage on Axon Enterprise in a research note on Wednesday, July 17th. They set a “buy” rating and a $385.00 price objective for the company. JMP Securities upped their target price on Axon Enterprise from $375.00 to $430.00 and gave the stock an “outperform” rating in a research note on Thursday, September 12th. Northland Securities boosted their price target on Axon Enterprise from $330.00 to $365.00 and gave the company an “outperform” rating in a report on Thursday, August 8th. Finally, Robert W. Baird upped their price objective on Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 10th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $365.38.

Institutional Investors Weigh In On Axon Enterprise

Several large investors have recently bought and sold shares of AXON. Vanguard Group Inc. lifted its position in shares of Axon Enterprise by 2.7% in the first quarter. Vanguard Group Inc. now owns 8,143,306 shares of the biotechnology company’s stock valued at $2,547,878,000 after acquiring an additional 212,401 shares in the last quarter. Sands Capital Management LLC raised its stake in Axon Enterprise by 0.6% in the 4th quarter. Sands Capital Management LLC now owns 2,628,652 shares of the biotechnology company’s stock valued at $679,060,000 after purchasing an additional 16,347 shares during the last quarter. Norges Bank purchased a new position in Axon Enterprise in the 4th quarter valued at $195,406,000. Westfield Capital Management Co. LP boosted its stake in Axon Enterprise by 5.1% during the 4th quarter. Westfield Capital Management Co. LP now owns 731,721 shares of the biotechnology company’s stock worth $189,025,000 after purchasing an additional 35,528 shares during the last quarter. Finally, Motley Fool Asset Management LLC raised its position in shares of Axon Enterprise by 238.7% in the first quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company’s stock valued at $153,981,000 after buying an additional 346,838 shares during the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.